Adolphs R, Tranel D Impaired judgments of sadness but not happiness following bilateral amygdala damage. J Cogn Neurosci. 2004 Apr;16(3):453-62. doi: 10.1162/089892904322926782.
Ahmed S, Haigh AM, de Jager CA, Garrard P Connected speech as a marker of disease progression in autopsy-proven Alzheimer's disease. Brain. 2013 Dec;136(Pt 12):3727-37. doi: 10.1093/brain/awt269. Epub 2013 Oct 18.
Beauchet O, Launay CP, Annweiler C, Allali G Hippocampal volume, early cognitive decline and gait variability: which association? Exp Gerontol. 2015 Jan;61:98-104. doi: 10.1016/j.exger.2014.11.002. Epub 2014 Nov 6.
Eyigoz E, Mathur S, Santamaria M, Cecchi G, Naylor M Linguistic markers predict onset of Alzheimer's disease. EClinicalMedicine. 2020 Oct 22;28:100583. doi: 10.1016/j.eclinm.2020.100583. eCollection 2020 Nov.
Hu X, Fernie AR, Yan J Deep learning in regulatory genomics: from identification to design. Curr Opin Biotechnol. 2023 Feb;79:102887. doi: 10.1016/j.copbio.2022.102887. Epub 2023 Jan 12.
Jiang Y, Yang M, Wang S, Li X, Sun Y Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun (Lond). 2020 Apr;40(4):154-166. doi: 10.1002/cac2.12012. Epub 2020 Apr 11.
Klein-Koerkamp Y, Beaudoin M, Baciu M, Hot P Emotional decoding abilities in Alzheimer's disease: a meta-analysis. J Alzheimers Dis. 2012;32(1):109-25. doi: 10.3233/JAD-2012-120553.
Pakhomov SV, Hemmy LS A computational linguistic measure of clustering behavior on semantic verbal fluency task predicts risk of future dementia in the nun study. Cortex. 2014 Jun;55:97-106. doi: 10.1016/j.cortex.2013.05.009. Epub 2013 Jun 14.
Wilson J, Allcock L, Mc Ardle R, Taylor JP, Rochester L The neural correlates of discrete gait characteristics in ageing: A structured review. Neurosci Biobehav Rev. 2019 May;100:344-369. doi: 10.1016/j.neubiorev.2018.12.017. Epub 2018 Dec 13.
Wilson SM, Eriksson DK, Schneck SM, Lucanie JM A quick aphasia battery for efficient, reliable, and multidimensional assessment of language function. PLoS One. 2018 Feb 9;13(2):e0192773. doi: 10.1371/journal.pone.0192773. eCollection 2018. Erratum In: PLoS One. 2018 Jun 15;13(6):e0199469.
Yamaguchi T, Maki Y, Yamaguchi H Yamaguchi Facial Expression-Making Task in Alzheimer's Disease: A Novel and Enjoyable Make-a-Face Game. Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):248-57. doi: 10.1159/000339425. Epub 2012 Jun 20.
Multimodal Deep Learning for the Diagnosis and Assessment of Alzheimer's Disease
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
